A study comparing oral glucose-lowering agents to insulin for gestational diabetes found no non-inferiority in preventing large-for-gestational-age infants.
FDA allows first pivotal trial of an in vivo gene editing treatment from Intellia
The FDA cleared Intellia Therapeutics to run a Phase III study of its CRISPR-based therapy for transthyretin (ATTR) amyloidosis with cardiomyopathy, paving the way for
October 19, 2023